27 recruiting, 14 not yet recruiting, 8 completed, 7 unknown. 39 Phase 2, 21 Phase 1, 5 Phase 3, 3 Early Phase 1, 2 Not applicable.
Follow TNBC - Triple-Negative Breast Cancer: new trials by email Literature Review of TNBC - Triple-Negative Breast Cancer trials Research Report on TNBC - Triple-Negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | CoRegen, Inc. | 67 | 2026-11-01 | 2026-10-02 |
| A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. YF550 - Solid Tumor (Phase I), Ovarian Cancer | Phase 1 | Not yet recruiting | InventisBio Yiqi Beijing Limited | 204 | 2026-10-01 | 2026-10-26 |
| Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery BCS + SRG-514, BCS - TNBC - Triple-Negative Breast Cancer | Phase 3 | Not yet recruiting | SURGE Therapeutics | 400 | 2026-10-01 | 2026-07-23 |
| Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) Medical record use research - TNBC - Triple-Negative Breast Cancer | Not yet recruiting | Yeon Hee Park | 2000 | 2026-09-14 | 2026-09-18 | |
| Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Live biotherapeutic product: MO-03 1 capsule PO BID - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Yuan Yuan | 50 | 2026-09-01 | 2026-08-05 |
| Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC RYZ211/212 - Metastatic Urothelial Carcinoma, Breast Cancer | Early Phase 1 | Recruiting | RayzeBio, Inc. | 40 | 2026-06-15 | 2026-10-13 |
| ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation Pembrolizumab, Radiotherapy, Axatilimab - TNBC - Triple-Negative Breast Cancer, Breast Cancer | Phase 2 | Not yet recruiting | Stephen Shiao | 34 | 2026-06-01 | 2026-04-20 |
| Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer TNBC - Triple-Negative Breast Cancer | Recruiting | Fudan University | 300 | 2026-05-15 | 2026-04-24 | |
| A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation Inavolisib in Combination With Eribulin - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Hu Hai | 26 | 2026-03-15 | 2026-03-02 |
| Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC Sacituzumab tirumotecan, Toripalimab - TNBC - Triple-Negative Breast Cancer, PD-L1 Positive | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 41 | 2025-12-01 | 2025-11-24 |
| Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer Toripalimab, PCb-EC, PCb - TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 216 | 2025-11-26 | 2025-12-02 |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies There are no interventions in this observational study. - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Recruiting | Tempus AI | 900 | 2025-10-27 | 2026-09-03 | |
| Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab - TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 37 | 2025-09-25 | 2026-01-20 |
| A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC). JS004 in combination with toripalimab and chemotherapy, Toripalimab and chemotherapy, Chemotherapy - TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Shengjing Hospital | 125 | 2025-09-01 | 2025-08-03 |
| SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers SC-101 - TNBC - Triple-Negative Breast Cancer, HR+ Breast Cancer | Phase 2 | Recruiting | Tianjin ConjuStar Biologics Co., Ltd. | 120 | 2025-08-26 | 2026-10-29 |
| Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer Ivonescimab, Carboplatin, Docetaxel - TNBC, TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 34 | 2025-07-25 | 2026-08-04 |
| SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer SHR-A2102 ; Adebrelimab injection - TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 52 | 2025-06-23 | 2025-06-23 |
| NearWave Optical Molecular Monitoring NearWave monitoring - Breast Cancer, HER2-positive Breast Cancer | Not applicable | Active not recruiting | Indiana University | 5 | 2025-03-07 | 2026-10-27 |
| Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer Dupilumab, Pembrolizumab, Paclitaxel - Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Early Phase 1 | Recruiting | Rima Patel | 15 | 2025-03-05 | 2026-05-14 |
Showing 20 of 71. Sign in to see all of them.
Triple Negative Breast Neoplasms (71) · Breast Neoplasms (25) · Carcinoma, Non-Small-Cell Lung (9) · Ovarian Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Ovarian Epithelial (4) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Carcinoma, Transitional Cell (3) · Neoplasm Metastasis (3) · Neoplasm, Residual (3) · Neoplasms (3) · Prostatic Neoplasms (3) · Small Cell Lung Carcinoma (3) · Carcinoma, Renal Cell (2)
Breast Diseases (71) · Neoplasms by Site (71) · Skin Diseases (71) · Skin and Connective Tissue Diseases (71) · Neoplasms (68) · Breast Neoplasms (46) · Neoplasms by Histologic Type (14) · Neoplasms, Glandular and Epithelial (13) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Respiratory Tract Neoplasms (12) · Thoracic Neoplasms (12) · Bronchial Neoplasms (11) · Carcinoma (11) · Carcinoma, Bronchogenic (11)
Carboplatin (6) · pembrolizumab (6) · toripalimab (5) · 130-nm albumin-bound paclitaxel (4) · Paclitaxel (4) · olaparib (4) · talazoparib (4) · Bevacizumab (3) · Drug Therapy (3) · camrelizumab (3) · durvalumab (3) · eribulin (3) · CB-839 (2) · Capecitabine (2) · Cyclophosphamide (2)
Fudan University (9) · Calithera Biosciences, Inc (2) · Henan Cancer Hospital (2) · Indiana University (2) · Memorial Sloan Kettering Cancer Center (2) · Stephen Shiao (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Abramson Cancer Center at Penn Medicine (1) · Arcus Biosciences, Inc. (1) · Avenzo Therapeutics, Inc. (1) · BeiGene (1) · Beijing 302 Hospital (1) · Cedars-Sinai Medical Center (1) · CoRegen, Inc. (1) · CytoDyn, Inc. (1)
United States (35) · China (19) · Australia (6) · Canada (3) · France (3) · Spain (3) · Bulgaria (2) · Moldova (2) · New Zealand (2) · Poland (2) · South Korea (2) · Ukraine (2) · Belgium (1) · Georgia (1) · Germany (1)
Sam Whiting, MD, PhD (2) · Yuan Yuan, MD (2) · Ashley Ward, MD (1) · Atif Khan, MD (1) · Binghe NA Xu (1) · Biyun Wang, Professor (1) · Etienne Brain (1) · Freddy Escorcia (1) · Funda Meric-Burnstam, MD (1) · George T Budd, MD (1) · Heying Duan (1) · Jackie Walling, MBChB, PhD (1) · Jennifer Zhang, MD (1) · Jin Sun Lee-Bitar, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 34903471, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36135712, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 37857711, PMID 38086377, PMID 38104577, PMID 38180338, PMID 38211606, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40471518, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42410111, PMID 42530945, PMID 42545411, PMID 42581203, PMID 42619946, PMID 42811224
R01CA240983 (1)